The KINECT-DCP trial evaluated the efficacy and safety of valbenazine in patients with dyskinesia due to cerebral palsy who experience choreiform movements.

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in pediatric and adult participants who ...

Welcome to Vibe Check, Unbothered’s wellness column aimed at revolutionizing how Black folx think about self-care, because “self-care” is not always synonymous with Black existence. A safe space for ...

Biosciences announced that its Phase 3 KINECT-DCP study evaluating the efficacy, safety, and tolerability of valbenazine in ...

Cerebral palsy (CP) remains one of the most common neurodevelopmental disorders affecting motor function from early life. Research in this field spans genetic, neurobiological and rehabilitative ...

Adult stem cell therapy quickly and significantly improves recovery of motor function in an animal model for the ischemic brain injury that occurs in about 10 percent of babies with cerebral palsy, ...

Spastic cerebral palsy is a disorder that involves muscle stiffness. Symptoms and signs may include difficulty walking, trouble manipulating objects, and vision, hearing, or speech challenges.

Millions of Americans with chronic health conditions are facing a major life transition. About 4.5 million young people with pediatric-onset disabilities, meaning disabilities they are born with, are ...

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Phase 3 KINECT®-DCP study evaluating the efficacy, safety ...